[b]CHINA-PLAY - RIESENCHANCE - einige 100%[/b] - 500 Beiträge pro Seite

[harry007]

siehe auch Thread Thread: ##brandheisser Chinaplay##die Jahrtausend-Chance##

- Pharmaprint von 0.96875 US$ auf 1.65625 US$ (+69%)
- Pharmaprint wird Big-Player im Health-Bereich Chinas.
- Pharmaprint sieht sich einem 20 Milliarden US$ Markt gegenüber
- bei einer Marktkapitalisierung von nur ca 20 Mill. US$
- Pharmaprint in München/Frankfurt/Berlin unter WKN 907072

Während der Börsenzeit gestern um 48% gestiegen
- von 0.96875 US$ auf 1.43750 US$
nachbörslich weiter gestiegen
- nachbörslich bis auf 1,65625 US$ gestiegen (bei sehr hohem Volumen)
nachzusehen unter:

http://toplist.island.com/SERVICE/TOPLIST?AH=Y

Und hier die Meldung mit Quelle:

http://biz.yahoo.com/prnews/000202/ca_pharmap_1.html

Wednesday February 2, 9:01 am Eastern Time
Company Press Release
SOURCE: PharmaPrint Inc.

PharmaPrint and Subsidiary of China New Industries Form $12 Million Joint
Venture Targeting China`s US$20 Billion Market

The Parties Reach Binding Legal Agreement Subject to Final Approval Of Respective Boards

IRVINE, Calif., Feb. 2 /PRNewswire/ -- PharmaPrint Inc. (Nasdaq: PPRT - news), a leader in the development of health
products from natural plant extracts,
announced today the successful completion of a binding legal agreement with ShenZhen ZeGu Venture Capital Co., Ltd., a
wholly owned subsidiary of China New
Industries Investment Co., Ltd. The companies will form a joint business entity that will sell a wide range of herbal-based
health products in China and the Asia
Pacific region utilizing the proprietary PharmaPrint(TM) Process.

Under the terms of the agreement, PharmaPrint owns 51% of the new entity, principally by contributing exclusive rights to its
proprietary technology. China New
Industries will contribute $6 million in cash and receive in return 49% of the joint venture equity shares. China New Industries`
initial contribution is $1.5 million in
cash; the remaining capital contributions will be provided in installments over a two-year period in accordance with relevant
laws. PharmaPrint will pay a nominal
administrative fee at the time of distribution. PharmaPrint will transfer use rights to its technology with respect to
manufacturing, testing and quality control of
herbal-based health products; provide necessary technical assistance and services; and grant an exclusive license for the use
of the PharmaPrint patents, trade
secrets and trademarks in China and the Asia Pacific regions, while retaining title to these technologies.

The initial stage of the of the joint venture will focus on promotion and marketing of PharmaPrint`s herbal-based health
products produced from raw materials and/or
semi-finished products. Once the initial stage is completed, the focus of the joint venture entity may also include certain
phases of the production process.

This agreement is subject to approval by both parties` governing boards. The Company anticipates that a formal joint venture
contract and articles of association will
be completed within the first quarter of 2000.

``We`re obviously very pleased to form this strategic alliance with China New Industries,`` said C. Richard Piazza,
PharmaPrint`s Chairman of the Board, President
and Chief Executive Officer. ``This joint venture entity provides a gateway into the China and the Asia Pacific region and a
tremendous opportunity to distribute
PharmaPrint`s current line of herbal health products, products under development and future products. This new distribution
channel is part of the Company`s overall
marketing strategy of developing multiple revenue streams for the PharmaPrint(TM) Process worldwide,`` concluded Mr.
Piazza. The Company recently announced
two notices of allowance for patent applications for saw palmetto and St. John`s wort.

The Chinese people have been using herbs for several thousand years. ``China`s 1.3 billion people represent an enormous
market potential for herbal products and
nutritional foods in this region,`` said Xian Ding Weng, President of China New Industries Investment Co., Ltd. ``Approximately
US$20 billion is spent each year.
We believe products utilizing the unique PharmaPrint(TM) Process technology will provide Asian consumers with the
assurance that they are getting quality herbal
and nutritional food products, in a capsule form that is more convenient than the traditional Chinese blending of raw herbs. We
look forward to introducing the
PharmaPrint products to the Asian consumers as soon as the appropriate documentation is completed and approvals are
obtained.``

About China New Industries Investment Co., Ltd.

China New Industries Investment Co., Ltd. is a major Chinese conglomerate with leadership positions in many areas. The
Company specializes in investing in
businesses that have unique technologies that have demonstrated highly promising market potentials. The Company was
recognized by Business Week as one of the
leading companies in China in terms of its innovative investment practices and impressive returns on assets.

About PharmaPrint

PharmaPrint develops, manufactures and markets dietary supplements, functional foods and pharmaceuticals derived from
natural plant extracts. The Company`s
proprietary PharmaPrint(TM) Process technology enables the precise identification and consistent replication of the active
ingredients from these extracts that are
scientifically believed to provide the desired health benefits.

``Safe Harbor`` Statement under the Private Securities Litigation Reform Act of 1995:

This press release includes forward looking statements that involve a high degree of financial, technological, regulatory and
competitive risks and uncertainties
inherent to early stage nutraceutical companies. These forward looking statements include, but are not limited to, the ability to
execute a legal agreement between
PharmaPrint and China New Industries and obtain respective board approval; the outcome of litigation with American Home
Products Corporation; the cost and
availability of botanical extracts; the cost and availability of manufacturing service contracts; the ability to obtain and enforce
patents; limited manufacturing
experience; dependence on third parties; uncertainties related to the PharmaPrint(TM) Process; government regulation and
uncertainty of product approvals; ability
to commercialize and market products in the U.S. and internationally; results of research and development and clinical and
toxicology studies; technological advances
by third parties; competition; future capital needs of the Company and general economic and business conditions;
uncertainties relating to Nasdaq rules, regulations
and procedures and their interpretation in the future; and uncertainties regarding the Company`s continued compliance with all
requirements to maintain listing of its
common stock on the Nasdaq National Market. Additional information on potential factors that could affect the Company`s
financial results are included in the
Company`s Registration Statement on Form S-8 dated July 6, 1999, and on Form 10-Q for the periods ended September 30,
1999, and on Form 10-K for the
year ended March 31, 1999.

For more information, contact the Company`s Website at www.pharmaprint.com.

SOURCE: PharmaPrint Inc.

[harry007]

Da ich hier anscheinend der Alleinunterhalter bin, werde ich um ca.
14.00Uhr noch den vorbörslichen Kurs reinstellen und mich dann ver-
abschieden. Ich bin auf jeden Fall für 1-2 Jahre in diesem Wert in-
vestiert.

[seitfallzieher]

O.k., harry007, Du mußt hier nicht alleine bleiben.
Rein charttechnisch sieht das glaub ich ganz gut aus.
Aber die fundamentals?
Und warum ging´s so lange bergab (seit listing!!)???

seitfallzieher

[DerWanderer]

Vielleicht deswegen:

Notice of Class Action Files Against PharmaPrint Inc., - PPRT - Brought By Kantrowitz, Goldhamer & Graifman


NEW YORK--(BUSINESS WIRE)--Jan. 7, 2000--Notice is hereby given that a lawsuit has been filed by the law firm of Kantrowitz, Goldhamer & Graifman, of Montvale, New Jersey on behalf of Plaintiff and a proposed class of purchasers of common stock of PharmaPrint, Inc. (NASDAQ:PPRT) against PharmaPrint Inc. ("PharmaPrint" of "Company") and certain officers and directors for the class period July 1, 1999 through November 15, 1999 ("Class Period"), in the U.S. District Court of New Jersey.
The complaint alleges that PharmaPrint and certain officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, by making false and misleading statements and omissions concerning the company`s distribution, its revenue and financial condition for the period ending September 30, 1999 inclusive of the period constituting its second quarter. As a result of these alleged violations, the price of common stock of PharmaPrint was artificially inflated during the Class Period. The complaint alleges that despite a dispute with its sole major customer, American Home Products Corp. ("AHP") which resulted in a virtual stoppage of orders from that customer, and a cancellation of the distribution agreement by American Home Products, which had a serious and materially negative effect on its revenues for the period ending September 30, 1999, defendants released positive information concerning the expansion of its distribution chain and failed to disclose the loss of its sole major customer and revenues until November 15, 1999.
Plaintiff seeks to recover damages on his own behalf and on behalf of the Class and are represented by the law firm of Kantrowitz, Goldhamer & Graifman. The firm has significant experience successfully prosecuting complex securities fraud class actions on behalf of defrauded investors.
If you were a purchaser of PharmaPrint shares during the Class Period, you may, not later than sixty (60) days from January 5, 2000, move the court to serve as lead plaintiff, if you so choose. In order to serve as lead plaintiff, however, you must meet certain legal requirements. You can see more information concerning this lawsuit on Kantrowitz, Goldhamer & Graifman`s website: www.kgglaw.com.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to this matter, please contact: Gary S. Graifman at Kantrowitz, Goldhamer & Graifman toll-free at 800/660-7843 or via Internet e-mail at [e-mail] or by writing, Kantrowitz, Goldhamer & Graifman, 210 Summit Avenue, Montvale, New Jersey 07645.
CONTACT: Kantrowitz, Goldhamer & Graifman
Gary S. Graifman, Esq.
1-800-660-7843 or 914/356-2570
TICKERS: NASDAQ:PPRT
KEYWORD: NEW JERSEY NEW YORK
INDUSTRY KEYWORD: LEGAL/LAW Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com Copyright 2000, Business Wire
Companies or Securities discussed in this article:
Symbol Name
NASDAQ:PPRT PharmaPrint Inc.


Hat jemand Inof`s zu E-NewMedia 885558 ?

Bye

Der Wanderer

[ak47int]

Fühl dich gedankt von mir, weil ich auf deinen thread hin und Chartansicht noch flugs zu 1,70 eingestiegen bin, bevor USA bei 2,125 gesclossen hat und uns morgen vielleicht noch glücklicher machen wird, da wir jetzt ja wohl wirklich einen klaren Chartausbruch beobachten können.

Danke und wo bleiben eigentlich die nachbörslichen Kurse ???

[harry007]

Vorbörsliche und nachbörsliche Kurse gibt es unter

http://www.isld.com/BookViewer/javaversion.htm#

In dem Java-Applet gibst Du das Kürzel PPRT ein, dann siehst Du wie
die Orders rein kommen, usw.. Das Applet aktualisiert sich selbst.

Unter

http://toplist.island.com/SERVICE/TOPLIST?SORT=0

bekommst Du die 20 vorbörslich meistgehandelten Aktien. Dies ist allerdings
eine reine HTML-Seite und für eine Aktualisierung mußt Du "Neu laden".

Ab ca. 14.00Uhr unserer Zeit werden die ersten vorbörslichen Orders
reinkommen.